Evidence map›Paper›PMID 40034121›Full record

ArticleiScience2025

Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers.

Sophia Liu, Julie Faitg, Charlotte Tissot, Dimitris Konstantopoulos, Ross Laws, Guillaume Bourdier, Pénélope A Andreux, Tracey Davey, Hector Gallart-Ayala, Julijana Ivanisevic and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sophia LiuDepartment of Radiology, University of Washington Medical Center, Box 358050, Seattle, WA 98109, USA.
Julie FaitgAmazentis, EPFL Innovation Park, Lausanne, Switzerland.
Charlotte TissotAmazentis, EPFL Innovation Park, Lausanne, Switzerland.
Dimitris KonstantopoulosGenevia Technologies Oy, 33100 Tampere, Finland.
Ross LawsElectron Microscopy Research Services, Newcastle University, Newcastle, UK.
Guillaume BourdierSyncrosome, Campus Luminy - Luminy Entreprises, 13288 Marseille, France.
Pénélope A AndreuxVandria, EPFL Innovation Park, Lausanne, Switzerland.
Tracey DaveyElectron Microscopy Research Services, Newcastle University, Newcastle, UK.
Hector Gallart-AyalaMetabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Julijana IvanisevicMetabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Anurag SinghAmazentis, EPFL Innovation Park, Lausanne, Switzerland.
Chris RinschAmazentis, EPFL Innovation Park, Lausanne, Switzerland.
David J MarcinekDepartment of Radiology, University of Washington Medical Center, Box 358050, Seattle, WA 98109, USA.
Davide D'AmicoAmazentis, EPFL Innovation Park, Lausanne, Switzerland.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Mechanisms underlying reversal of cardiac aging by urolithin a treatmentR01AG081395 · NIA · UNIVERSITY OF WASHINGTON · PI David J. Marcinek, MICHAEL REGNIER · 2024 to 2026
$3.2M
NIA NIH HHS R01 AG081395NIDDK NIH HHS P30 DK017047
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the primary cause of global mortality. Nutritional interventions hold promise to reduce CVD risks in an increasingly aging population. However, few nutritional interventions are proven to support heart health and act mostly on blood lipid homeostasis rather than at cardiac cell level. Here, we show that mitochondrial quality dysfunctions are common hallmarks in human cardiomyocytes upon heart aging and in chronic conditions. Preclinically, the post-biotic and mitophagy activator, urolithin A (UA), reduced both systolic and diastolic cardiac dysfunction in models of natural aging and heart failure. At a cellular level, this was associated with a recovery of mitochondrial ultrastructural defects and mitophagy. In humans, UA supplementation for 4 months in healthy older adults significantly reduced plasma ceramides clinically validated to predict CVD risks. These findings extend and translate UA's benefits to heart health, making UA a promising nutritional intervention to support cardiovascular function as we age.

Indexed as

Biological sciencesCardiovascular medicineHealth sciencesInternal medicineMedical specialtyMedicineNatural sciencesPhysiology

Identifiers

PMID40034121
PMCPMC11875685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.